Protalix BioTherapeutics
PLX
38 hedge funds and large institutions have $39.4M invested in Protalix BioTherapeutics in 2021 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 10 increasing their positions, 3 reducing their positions, and 4 closing their positions.
375% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 4
233% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 3
165% more capital invested
Capital invested by funds: $14.8M → $39.4M (+$24.5M)
65% more funds holding
Funds holding: 23 → 38 (+15)
7.68% more ownership
Funds ownership: 12.26% → 19.94% (+7.7%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
12% less call options, than puts
Call options by funds: $1.08M | Put options by funds: $1.23M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVH
Psagot Value Holdings
Tel Aviv,
Israel
|
+$12.2M |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$5.61M |
| 3 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$1.37M |
| 4 |
PF
Phoenix Financial
Givatayim,
Israel
|
+$1.14M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$690K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Burrage Capital Management
Boston,
Massachusetts
|
-$1.61M |
| 2 |
Group One Trading
Chicago,
Illinois
|
-$234K |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$85K |
| 4 |
Squarepoint
New York
|
-$80K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$36K |
PLX Hedge Fund Activity: Q1 2021 in Review
38 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q1 2021, worth a combined $39.4M — up 165% from $14.8M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new PLX positions and 4 closed out — a net gain of 15 holders — while 10 added to existing stakes and 3 trimmed.
The largest buyer was Psagot Value Holdings, adding an estimated $12.2M. The largest seller was Burrage Capital Management, cutting an estimated $1.61M.
- 38 institutional investors held Protalix BioTherapeutics (PLX) as of Q1 2021, up from 23 in Q4 2020.
- Funds reported $39.4M of Protalix BioTherapeutics stock for Q1 2021, up 165% quarter-over-quarter.
- 19 funds opened new Protalix BioTherapeutics positions in Q1 2021 and 4 closed out, a net change of +15 holders.
- The largest Protalix BioTherapeutics buyer in Q1 2021 was Psagot Value Holdings, an estimated $12.2M added.
- The largest Protalix BioTherapeutics seller in Q1 2021 was Burrage Capital Management, an estimated $1.61M sold.
Based on aggregated 13F filings for Q1 2021.